Ignite Creation Date:
2025-12-24 @ 1:13 PM
Ignite Modification Date:
2026-02-01 @ 8:14 AM
Study NCT ID:
NCT03047395
Status:
COMPLETED
Last Update Posted:
2024-12-11
First Post:
2017-02-07
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )
Sponsor:
AbbVie
Organization: